PEAT Act of 2026
Sponsored By: Representative Rulli, Michael A. [R-OH-6]
Introduced
Summary
Stops automatic reclassification of a biologic as a "biological product" based only on a clinically inactive protein. The Protecting Equal Access to Thyroid Act of 2026 would amend section 351(i)(1) of the Public Health Service Act so that a biologic may not be treated as a biological product solely because it contains a protein that is a clinically inactive component. The bill also makes a minor technical punctuation correction to that statutory text.
Personalized for You
How does this bill affect your finances?
Personalize government policy and PRIA will tell you what this bill means for your household, plus every other piece of legislation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Bill Overview
Analyzed Economic Effects
1 provisions identified: 1 benefits, 0 costs, 0 mixed.
Limits biologic reclassification for manufacturers
If enacted, regulators like the FDA would not be allowed to treat a biologic as a "biological product" only because it contains a clinically inactive protein. The rule would stop agencies from using an inactive protein as the sole basis for reclassification. This would reduce regulatory uncertainty and paperwork for biotech developers and manufacturers. The change would take effect upon enactment and would not create new funding, programs, or eligibility rules.
Sponsors & CoSponsors
Sponsor
Rulli, Michael A. [R-OH-6]
OH • R
Cosponsors
Rep. Harshbarger, Diana [R-TN-1]
TN • R
Sponsored 4/30/2026
Rep. Luttrell, Morgan [R-TX-8]
TX • R
Sponsored 5/13/2026
Babin
TX • R
Sponsored 5/14/2026
Roll Call Votes
No roll call votes available for this bill.
View on Congress.gov